"The in-license of Eltoprazine represents a major corporate milestone for Amarantus, moving the therapeutic pipeline from purely a pre-clinical pipeline with MANF, to a balanced pipeline with both clinical and pre-clinical assets," said David A. Lowe, PhD, member of the Amarantus Board of Directors. "The 5HT1a/1b pathway is emerging as a key biological pathway in the LID-space, and Eltoprazine is the most advanced drug candidate in this class. Adequately addressing LID in Parkinson's disease would represent a significant improvement to the standard of care for patients worldwide and is a significant commercial opportunity."


http://ir.stockpr.com/amarantus/company-news/...-discovery